BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

TEL AVIV, Israel, Jan. 17, 2025 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced today that its Board of Directors has approved a change in the number of its…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.